BeiGene’s Brukinsa Approved in China for Two Lymphoma Indications

China’s National Medical Products Administration has approved BeiGene’s Brukinsa (zanubrutinib) for certain adults with lymphoma.

The agency approved the kinase inhibitor for treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least one prior therapy. It also approved the drug for adults with mantle-cell lymphoma who have previously received at least one therapy.

The FDA granted Brukinsa accelerated approval in November 2019 for mantle-cell lymphoma in adults who have received at least one previous therapy.